Flash Finance

Wockhardt LimitedWOCKPHARMACorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,954.90
MCap ₹31,766 Cr · P/E 90.0
Wockhardt Limited — Stock analysis & AI research Wockhardt Limited — Multibagger AI analysis Wockhardt Limited — Seasonality — best & worst months Wockhardt Limited — Technical indicators & charts Wockhardt Limited — Technical setup — score, trend, support & resistance Wockhardt Limited — Live exchange announcements
📋 Stocks With Strong Quarterly Results📋 Small Cap Stocks List 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹929 Cr
Sales · Jun 2026
+25.9% YoY
₹192 Cr
Operating Profit · Jun 2026
+166.7% YoY
20.7%
OPM % · Jun 2026
+111.2% YoY
₹107 Cr
Net Profit · Jun 2026
+199.1% YoY
₹6.55
EPS · Jun 2026
+218.2% YoY

📝 Wockhardt Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Wockhardt Limited reported revenue of ₹929 crore for the quarter ended June 2026 (Q1 FY27), up 25.9% from ₹738 crore in the same quarter last year, and down 3.7% sequentially over the March 2026 quarter.

The company swung to a net profit of ₹107 crore from a net loss of ₹108 crore a year earlier. Earnings per share (EPS) came in at ₹6.55.

Operating profit stood at ₹192 crore — an operating margin (OPM) of 20.7%, compared with 9.8% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Wockhardt Limited posted revenue of ₹2,942 crore, a decline of 2.3% over FY25, with a net profit of ₹138 crore.

On a trailing-twelve-month (TTM) basis, revenue stands at ₹3,133 crore with a net profit of ₹353 crore.

Valuation snapshot

At the current price of ₹1,954.90, WOCKPHARMA has a market capitalisation of ₹31,766 crore and a trailing P/E of about 90.0.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 19th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 49.08%, foreign institutional investors (FIIs) 7.22%, domestic institutional investors (DIIs) 9.24%, the government 0.02%, public shareholders 34.44% of Wockhardt Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹31,766 Cr
Current Price ?
₹1,954.9
P/E ?
89.99above ind
Industry P/E ?
35.00
P/B ?
6.43
P/S ?
10.14
P/FCF ?
417.97
Enterprise Value ?
₹33,999 Cr
EV/EBITDA ?
54.57
PEG ?
2.09
Earnings Yield ?
1.2%
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
₹3,133 Cr
OPM ?
19.9%
Profit after tax (TTM) ?
₹353 Cr
EPS (TTM) ?
₹21.72
ROCE ?
8.0%
ROE ?
7.1%
ROA ?
4.1%
Growth
Sales — latest qtr ?
₹929 Cr
PAT — latest qtr ?
₹107 Cr
YoY qtr sales growth ?
25.9%
YoY qtr profit growth ?
199.1%
Sales growth (3y) ?
8%
Sales growth (5y) ?
4%
Profit growth (3y) ?
43%
Profit growth (5y) ?
-19%
Financial Health
Debt ?
₹2,233 Cr
Debt to Equity ?
0.45
Interest Coverage ?
1.3
Current Ratio ?
N/A
Ownership
Promoter holding ?
49.08%
Change in promoter holding ?
-0.01%
Pledged percentage ?
N/A
Market
Return 3 months ?
2.9%
Return 6 months ?
40.1%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 699678644753701700739809721743738782457965929 +25.9% -3.7%
Operating Profit 453165137-5991110128647217828225192 +166.7% -14.7%
Other Income -1-64024810309815-7721156731 +140.3% -53.7%
Interest 8376791117773737360484855605052 +8.3% +4.0%
Depreciation 665655705558545555535653655355 -1.8% +3.8%
Profit Before Tax -105-193-115-106-87-180-6-921-22-1095428189116 +206.4% -38.6%
Net Profit -102-237-115-113-86-177-16-1620-45-1085428164107 +199.1% -34.8%
EPS -6.66-14.44-9.30-1.05-5.76-11.02-0.95-1.470.91-1.54-5.544.803.6310.226.55 +218.2% -35.9%
OPM % 6.4% 0.4% 2.5% 6.8% 5.3% -8.4% 12.3% 13.6% 17.8% 8.6% 9.8% 22.8% 6.1% 23.3% 20.7% +111.2% -11.2%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹3,012 Cr ₹2,942 Cr ₹3,133 Cr -2.3%
Operating Profit ₹393 Cr ₹503 Cr ₹623 Cr +28.0%
OPM % 13.05% 17.10% 19.89% +31.0%
NPM % -1.89% 4.69% 11.27% +348.1%
Other Income ₹62 Cr ₹26 Cr ₹134 Cr -58.1%
Depreciation ₹217 Cr ₹227 Cr ₹226 Cr +4.6%
Interest ₹254 Cr ₹213 Cr ₹217 Cr -16.1%
EBIT ₹176 Cr ₹276 Cr ₹397 Cr +56.8%
PBT ₹-16 Cr ₹162 Cr ₹387 Cr +1112.5%
Tax ₹18 Cr — ₹9 Cr —
Net Profit ₹-57 Cr ₹138 Cr ₹353 Cr +342.1%
EPS ₹-3.05 ₹13.11 ₹25.20 +529.8%
Material Cost ₹878 Cr — ₹342 Cr —
Employee Cost ₹485 Cr — ₹203 Cr —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 72778181 +0.0%
Reserves 3,2823,2824,2724,859 +13.7%
Borrowings 2,1842,3562,0212,233 +10.5%
Other Liabilities 2,1131,8991,7261,442 -16.5%
Total Liabilities 7,6517,6148,1008,615 +6.4%
Fixed Assets 3,0422,8812,7364,499 +64.4%
CWIP 1,5391,7222,033671 -67.0%
Investments 00422412 -2.4%
Other Assets 3,0703,0112,9093,033 +4.3%
Total Assets 7,6517,6148,1008,615 +6.4%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 153219-22390 +1872.7%
Cash from Investing Activity -118-138-780-241 +69.1%
Cash from Financing Activity -315334409-54 -113.2%
Net Cash Flow -280415-39395 +124.2%
Free Cash Flow 2369-37776 +120.2%
CFO/OP 162%274%-13%63% +584.6%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 110818064 -20.0%
Inventory Days 216201234286 +22.2%
Days Payable 285240191182 -4.7%
Cash Conversion Cycle 4141123168 +36.6%
Working Capital Days -186-148-2389 +487.0%
ROCE % -0%-1%4%8% +100.0%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 49.09%49.09%49.09%49.09%49.08% -0.0%
FIIs 7.29%7.10%7.00%7.09%7.22% +1.8%
DIIs 11.00%11.00%10.55%10.96%9.24% -15.7%
Government 0.02%0.02%0.02%0.04%0.02% -50.0%
Public 32.60%32.79%33.36%32.84%34.44% +4.9%
No. of Shareholders 1,46,9181,37,9461,42,2741,39,0161,66,518 +19.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Wockhardt Limited's revenue in Q1 FY27?
Wockhardt Limited reported revenue of ₹929 crore for the quarter ended June 2026 (Q1 FY27), up 25.9% from ₹738 crore in the same quarter last year, and down 3.7% sequentially over the March 2026 quarter.
What was Wockhardt Limited's net profit in Q1 FY27?
The company swung to a net profit of ₹107 crore from a net loss of ₹108 crore a year earlier. Earnings per share (EPS) came in at ₹6.55.
What is WOCKPHARMA's market capitalisation and P/E ratio?
At the current price of ₹1,954.90, WOCKPHARMA has a market capitalisation of ₹31,766 crore and a trailing P/E of about 90.0.
Who owns Wockhardt Limited? (shareholding pattern)
As of Jun 2026, promoters held 49.08%, foreign institutional investors (FIIs) 7.22%, domestic institutional investors (DIIs) 9.24%, the government 0.02%, public shareholders 34.44% of Wockhardt Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI